Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
Author:
Affiliation:
1. Memorial Sloan Kettering Cancer Center New York NYUSA
2. Division of Hematology and Oncology Vanderbilt University Nashville TNUSA
3. Division of Hematology and Oncology University of Alabama at Birmingham Birmingham AL USA
Funder
Celgene
AbbVie
Amgen
Sanofi
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16130
Reference62 articles.
1. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
3. Evaluation of Minimal Residual Disease (MRD) by Next Generation Sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial;Avet‐Loiseau H.;Blood,2015
4. Evaluation of sustained Minimal Residual Disease (MRD) negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D‐Rd) or Bortezomib Plus Dexamethasone (D‐Vd): analysis of pollux and castor;Avet‐Loiseau H.;Blood,2018
5. Curing myeloma at last: defining criteria and providing the evidence
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Measurable residual disease after CAR T-cell therapy;Seminars in Hematology;2023-01
2. “Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow;Frontiers in Oncology;2022-11-28
3. Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy;Leukemia & Lymphoma;2022-09-28
4. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma;Annals of Laboratory Medicine;2022-09-01
5. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy;American Journal of Hematology;2022-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3